Perseus Proteomics Inc. (TYO:4882)

Market Cap	3.57B -62.3%
Revenue (ttm)	140.41M +26.1%
Net Income	-758.12M
EPS	-51.41
Shares Out	14.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,420,600
Average Volume	2,495,075
Open	218.00
Previous Close	216.00
Day's Range	218.00 - 244.00
52-Week Range	203.00 - 1,072.00
Beta	0.38
RSI	51.63
Earnings Date	May 14, 2026

About Perseus Proteomics

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2001
• Employees: 32
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4882

Financial Performance

In fiscal year 2025, Perseus Proteomics's revenue was 120.00 million, an increase of 20.00% compared to the previous year's 100.00 million. Losses were -904.00 million, -18.12% less than in 2024.